• PCV54 PATTERNS OF THERAPY, HEALTH CARE UTILIZATION, AND HEALTH CARE COSTS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) INITIATING THERAPY WITH SILDENAFIL- FINDINGS FROM RETROSPECTIVE ANALYSES OF ADMINISTRATIVE HEALTH CARE CLAIMS D ...

    Nov 1, 2010, 00:00

  • PCV48 ST. VINCENTS PRIVATE HOSPITAL VENOUS THROMBOEMBOLISM PREVENTION PROJECT- ANALYSIS OF REDUCED COST AND IMPROVED CLINICAL OUTCOMES

    Nov 1, 2010, 00:00

  • PHP32 PROBABILISTIC SENSITIVITY ANALYSIS-A NECESSARY EXTRA?

    Nov 1, 2010, 00:00

  • PHP123 PHARMACY NETWORK DEVELOPMENT DURING ECONOMIC TRANSITION IN POLAND

    Nov 1, 2010, 00:00

  • PMS79 USE OF PATIENT-REPORTED OUTCOMES IN ON-LINE COMMUNITIES TO CONDUCT OBSERVATIONAL COMPARATIVE EFFECTIVENESS RESEARCH- A PILOT STUDY IN RHEUMATOID ARTHRITIS

    Nov 1, 2010, 00:00

  • PCN17 NO CONCLUSIVE EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS) FOR IMPROVED SURVIVAL WITH SECOND-LINE TREATMENT OPTIONS, IN PATIENTS WITH METASTATIC HORMONEREFRACTORY PROSTATE CANCER (MHRPC) PREVIOUSLY TREATED WITH DOCETAXEL

    Nov 1, 2010, 00:00

  • PDB28 HEALTH INSURANCE COST OF DIABETES MELLITUS IN HUNGARY- A COST OF ILLNESS STUDY

    Nov 1, 2010, 00:00

  • PHP34 PATIENT ACCESS TO INNOVATIVE MEDICINES IN HUNGARY

    Nov 1, 2010, 00:00

  • PCN66 ECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE TREATMENT OF ADVANCED COLON-RECTUM CANCER IN CHINA

    Nov 1, 2010, 00:00

  • PMC11 ARE THRESHOLD RANGES FOR COST PER QALY A BARRIER TO RESEARCH FOR LIFE EXTENDING TREATMENTS

    Nov 1, 2010, 00:00

  • PSS20 COST-UTILITY ANALYSIS OF A PRN (AS NEEDED) TREATMENT SCHEDULE WITH RANIBIZUMAB (LUCENTIS) IN WET AMD BASED ON CLINICAL EVIDENCE

    Nov 1, 2010, 00:00

  • PIN55 RISK SCORES PREDICTING RESOURCE USE OF HEPATITIS C PATIENTS IN GERMANY-AN ANALYSIS OF SICK FUND CLAIMS DATA

    Nov 1, 2010, 00:00

  • PHP18 SCIENTIFIC EVIDENCE FOR THE RELATIONSHIP BETWEEN PHARMACEUTICAL BUDGET OF HEALTH INSURANCE FUND AND THE POLITICAL ELECTION CIRCLES IN HUNGARY

    Nov 1, 2010, 00:00

  • PCN26 ESTIMATION OF THE EPIDEMIOLOGICAL EFFECT OF RITUXIMAB FOR THE TREATMENT OF AGGRESSIVE NON-HODGKIN LYMPHOMA

    Nov 1, 2010, 00:00

  • PDB66 THE 8-ITEM MORISKY MEDICATION ADHERENCE SCALE MMAS- TRANSLATION AND VALIDATION STUDY OF THE MALAYSIAN VERSION

    Nov 1, 2010, 00:00

  • PCN117 UTILITY ELICITATION STUDY IN THE UK GENERAL PUBLIC FOR LATE STAGE CHRONIC LYMPHOCYTIC LEUKEMIA

    Nov 1, 2010, 00:00

  • PND19 A LONG-TERM COST-EFFECTIVENESS MARKOV MODEL COMPARING DISEASE MODIFYING TREATMENTS IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY

    Nov 1, 2010, 00:00

  • PIH9 COST COMPARISON OF MIDWIFE-LED VERSUS OTHER MODELS OF CARE FOR CHILDBEARING WOMEN FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2010, 00:00

  • PCN157 REASONS FOR DISCONTINUATION OF HORMONAL THERAPY IN BREAST CANCER PATIENTS ACROSS FIVE EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PIH64 A CONCEPTUAL FRAMEWORK FOR A PATIENT REPORTED OUTCOMES MEASURE OF ATTITUDES TOWARD COMPLEMENTARY AND ALTERNATIVE MEDICINE IN MENOPAUSE

    Nov 1, 2010, 00:00

  • PRS20 OUTCOMES ASSOCIATED WITH IATROGENIC PNEUMOTHORAX

    Nov 1, 2010, 00:00

  • PSY27 A HEALTH ECONOMIC EVALUATION OF THE SWITCH OF ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN PATIENTS WITH RENAL FAILURE UNDERGOING HEMODIALYSIS

    Nov 1, 2010, 00:00

  • PCN135 IMPROVEMENT IN QUALITY OF LIFE OUTCOMES IN INTERFERONALPHA TREATED PATIENTS COMPARED TO SUNITINIB IN ADVANCE OR METASTATIC RENAL CELL CARCINOMA

    Nov 1, 2010, 00:00

  • PMC57 BIAS IS WORSE THAN NOISE- HANDLING MISSING DATA FOR CONFOUNDERS IN OBSERVATIONAL STUDIES

    Nov 1, 2010, 00:00

  • PCV35 POTENTIAL DRUG-DRUG INTERACTIONS RELATED TO ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN TAIWAN

    Nov 1, 2010, 00:00

  • PMC50 TRANSLATION, LINGUISTIC VALIDATION AND ELECTRONIC ADMINISTRATION IN THE INDIAN LANGUAGES- A CASE STUDY HIGHLIGHTING THE SPECIAL DIFFICULTIES THAT EXIST AT THIS INTERSECTION

    Nov 1, 2010, 00:00

  • PDB73 THE PANORAMA PAN-EUROPEAN SURVEY- HYPOGLYCAEMIA ASSOCIATED WITH DIFFERENT PHARMACOLOGICAL TREATMENTS FOR TYPE 2 DIABETES

    Nov 1, 2010, 00:00

  • PMC20 THE OPTIMAL NUMBER OF MONTE CARLO SIMULATIONS TO BE PERFORMED IN PROBABILISTIC SENSITIVITY ANALYSIS- EMPIRICAL EVIDENCE FROM ECONOMIC MODELS CONSTRUCTED FOR SUBMISSION TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

    Nov 1, 2010, 00:00

  • PMS9 HEALTH-RELATED QUALITY OF LIFE IN INDIAN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2010, 00:00

  • PCN8 IDENTIFYING KEY PROCEDURES IN HEPATOCELLULAR CARCINOMA PATIENTS WITH HIGHEST PAYER BUDGET IMPACT IN A COMMERCIALLY INSURED POPULATION IN THE UNITED STATES

    Nov 1, 2010, 00:00

  • PMS24 OSTEOPOROSIS COSTS IN ITALY. INTERIM RESULTS OF THE BLOCK STUDY

    Nov 1, 2010, 00:00

  • PHP12 PHYSICIANS VIEWS ON BIOMEDICAL TECHNOLOGY IN GREECE

    Nov 1, 2010, 00:00

  • PCV14 ASPIRIN USE IS NOT ASSOCIATED WITH REDUCED MYOCARDIAL INFARCTION IN ELDERLY WITH TYPE 2 DIABETES WITH OR WITHOUT PRIOR HISTORY OF CARDIOVASCULAR DISEASE

    Nov 1, 2010, 00:00

  • PCV73 ECOMOMIC EVALUATION OF COMBINATION THERAPY FOR HYPERTENSION IN HIGH RISK PATIENTS IN SWEDEN

    Nov 1, 2010, 00:00

  • PHP46 COSTS OF TREATING TERMINAL PATIENTS IN DIFFERENT BELGIAN HEALTH CARE SETTINGS

    Nov 1, 2010, 00:00

  • PMC32 MINIMALLY IMPORTANT DIFFERENCE OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q)

    Nov 1, 2010, 00:00

  • PDB91 TREATMENT PATTERNS AND ACHIEVEMENT OF THERAPEUTIC GOALS IN A COHORT OF TYPE 2 DIABETES MELLITUS PATIENTS TREATED IN THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM (PHCS)- INITIAL REPORTS OF DIAPS 79 STUDY

    Nov 1, 2010, 00:00

  • PSY53 ORGANIZATION OF ACUTE PAIN SERVICE (APS) IN THE HUNGARIAN HOSPITAL SETTING

    Nov 1, 2010, 00:00

  • PUK24 A COST-UTILITY ANALYSIS OF CINACALCET IN SECONDARY HYPERPARATHYROIDISM (SHPT) IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PMS68 PHYSICIANS STATED PREFERENCES OVER BENEFITS AND RISKS ASSOCIATED WITH NSAID USE IN PATIENTS WITH OSTEOARTHRITIS IN UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PMS42 COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PMH53 FACTOR STRUCTURE OF A SOCIAL SUPPORT SCALE FOR ADOLESCENTS TREATED FOR SUBSTANCE USE DISORDER

    Nov 1, 2010, 00:00

  • PCV112 QUALITY OF LIFE AND DEPRESSION AMONG ADULTS WITH TYPE 2 DIABETES MELLITUS, HYPERTENSION, AND OBESITY

    Nov 1, 2010, 00:00

  • PUK25 USING GENETIC POLYMORPHISM AS A STRATEGY TO ESTIMATE THE POTENTIAL COST-EFFECTIVENESS OF PHARMACOLOGICAL CCR5 BLOCKADE IN DIALYSIS PATIENTS

    Nov 1, 2010, 00:00

  • PRS34 IMPROVED PREDICTION OF FINDING COPD PATIENTS BY LUNG FUNCTION PRE-SCREENING IN PRIMARY CARE

    Nov 1, 2010, 00:00

  • PHP38 HOW EQUITABLE OF HEALTH SERVICE USE AND GOVERNMENT SUBSIDIES IN THAILAND AFTER ACHIEVING UNIVERSAL COVERAGE?

    Nov 1, 2010, 00:00

  • PMH59 EVALUATION OF THE EFFECT OF ARIPIPRAZOLE ON QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA IN A PROSPECTIVE, MULTICENTRE, OPEN-LABEL STUDY

    Nov 1, 2010, 00:00

  • PMH67 FACTORS ASSOCIATED WITH ANTIPSYCHOTICS USE AMONG COMMUNITY-DWELLING OLDER PERSONS WITH DEMENTIA

    Nov 1, 2010, 00:00

  • PIH11 SOCIETAL IMPACT OF DIARRHEA IN YOUNG CHILDREN IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PCN109 COMPARISON OF HOSPITALIZATION BURDEN BETWEEN METASTATIC AND NON-METASTATIC MELANOMA PATIENTS IN A US POPULATION

    Nov 1, 2010, 00:00

  • PGI16 COST-EFFECTIVENESS OF ON-TREATMENT MONITORING OF HBSAG LEVELS TO PREDICT RESPONSE TO PEGINTERFERON-ALPHA-2A FOR HEPATITIS B TREATMENT UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2010, 00:00

  • PSY18 DIRECT MEDICAL COSTS OF LIQUID INTRAVENOUS IMMUNOGLOBULINS IN CHILDREN, ADOLESCENTS AND ADULTS IN SPAIN

    Nov 1, 2010, 00:00

  • PIN30 ECONOMIC EVALUATION OF DAPTOMYCIN AS FIRST-LINE THERAPY VERSUS DAPTOMYCIN AS RESCUE THERAPY AFTER VANCOMYCIN OR LINEZOLID FAILURE IN GRAM-POSITIVE BACTEREMIA TREATMENT

    Nov 1, 2010, 00:00

  • PHP97 TRAINING OF PHARMACEUTICAL SALES REPRESENTATIVES IN REGARD TO CHANGES IN HEALTH CARE POLICY IN GERMANY

    Nov 1, 2010, 00:00

  • PDB38 ADDITION OF INCRETIN-THERAPY TO METFORMIN IN TYPE-2DIABETES MELLITUS (T2DM)- COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS SITAGLIPTIN FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)

    Nov 1, 2010, 00:00

  • PCV58 SUBSTITUTION INFLUENCE FROM MARK DRUGS TO GENERICS IN THE ARTERIAL HYPERTENSION THERAPEUTIC COMPLIANCE AND THE DYSLIPEMIA IN A POPULATION SETTING

    Nov 1, 2010, 00:00

  • PMS14 FACTORS INFLUENCED ORAL OXICAM AND COXIBS EXPENDITURE AT A THAI TEACHING HOSPITAL, FISCAL YEAR 2006-2009

    Nov 1, 2010, 00:00

  • PHP22 THE USE OF ECONOMIC EVALUATIONS IN DECISION-MAKING AT MACRO LEVEL- A LITERATURE REVIEW

    Nov 1, 2010, 00:00

  • PMS74 CLAIMS-BASED SEVERITY INDEX FOR RHEUMATOID ARTHRITIS FROM HEALTH CARE CLAIMS DATA

    Nov 1, 2010, 00:00

  • PHP121 INSPECTION OF THE PHARMACEUTICAL COMPANIES IN IRAN BY INSPECTION SOFTWARE

    Nov 1, 2010, 00:00

  • PIN65 IMPACT OF HERPES ZOSTER AND POSTHERPETIC NEURALGIA ON PATIENTS QUALITY OF LIFE

    Nov 1, 2010, 00:00

  • PND31 IMPACT OF AN ADHERENCE PROGRAM, RUN AS A TELEPHONE INTERVENTION ON COMPLIANCE WITH SUBCUTANEOUS INTERFERON -1A FOR MULTIPLE SCLEROSIS PATIENTS USING A MAIL-ORDER PHARMACY

    Nov 1, 2010, 00:00

  • PIN20 A MODELED ECONOMIC EVALUATION OF RALTEGRAVIR COMPARED TO STANDARD PRACTICE IN AUSTRALIA FOR TREATMENT NAVE PATIENTS WITH HIV

    Nov 1, 2010, 00:00

  • PHP13 FACTORS ASSOCIATED WITH THE PROVISION OF LAPAROSCOPIC SURGERY IN THAILAND- RESULTS FROM THE NATIONWIDE INPATIENT DATABASE

    Nov 1, 2010, 00:00

  • PSS16 ECONOMIC EVALUATION OF A 100 WHEY-BASED, PARTIALLY HYDROLYZED INFANT FORMULA IN THE PREVENTION OF ATOPIC DERMATITIS AMONG FRENCH CHILDREN

    Nov 1, 2010, 00:00

  • PIN2 SURGICAL SITE INFECTION IN INDIA- A SYSTEMATIC REVIEW OF THE INCIDENCE AND ECONOMIC BURDEN

    Nov 1, 2010, 00:00

  • PSY28 COST OF INHIBITOR DEVELOPMENT IN PATIENTS WITH SEVERE HEMOPHILIA A IN SPAIN

    Nov 1, 2010, 00:00

  • PIN6 A MULTIVARIATE MODEL- PREDICTORS OF DISEASE PROGRESSION IN HIV/AIDS PATIENTS IN WESTERN NEW YORK

    Nov 1, 2010, 00:00

  • PSY58 AVAILABILITY OF AND ACCESS TO ORPHAN DRUGS-AN INTERNATIONAL COMPARISON OF PHARMACEUTICAL TREATMENTS FOR PULMONARY ARTERIAL HYPERTENSION, FABRY DISEASE, HEREDITARY ANGIOEDEMA AND CHRONIC MYELOID LEUKEMIA

    Nov 1, 2010, 00:00

  • PSS23 THE USE AND MISUSE OF ANTIBIOTICS FOR UPPER RESPIRATORY TRACT INFECTION

    Nov 1, 2010, 00:00

  • PMH28 EFFECT OF PREGABALIN ON COSTS AND CONSEQUENCES IN PATIENTS WITH REFRACTORY SEVERE GENERALIZED ANXIETY DISORDER AND CONCOMITANT SEVERE SYMPTOMS OF DEPRESSION IN DAILY MEDICAL PRACTICE

    Nov 1, 2010, 00:00

  • PHP129 ATTITUDES OF HUNGARIAN POPULATION TOWARD CO-PAYMENTS

    Nov 1, 2010, 00:00

  • PRS19 ASSESSMENT OF THE CLINICAL AND ECONOMIC IMPACT OF AIR LEAKS DURING POST-OPERATIVE PULMONARY SURGERY USING THE MEDICARE POPULATION

    Nov 1, 2010, 00:00

  • PCV106 THE MISSING PIECE BETWEEN TREATMENT EXPERIENCE AND INTENTION TO PERSIST-TESTING THE INTERNAL CONSISTENCY RELIABILITY AND PREDICTIVE VALIDITY OF ACCEPTABILITY

    Nov 1, 2010, 00:00

  • PRS22 COST OF COPD IN POLAND

    Nov 1, 2010, 00:00

  • PCN16 COST-EFFECTIVENESS ANALYSIS OF K-RAS TESTING AND CETUXIMAB FOR METASTATIC COLORECTAL CANCER IN JAPAN

    Nov 1, 2010, 00:00

  • PSS34 THE IMPACT OF POTENTIAL PILL SPLITTING ON GENERIC AND BRANDED FINASTERIDE UPTAKE

    Nov 1, 2010, 00:00

  • PCV4 EFFECT OF PRETREATMENT WITH ANGIOTENSIN-CONVERTING ENZYME INHIBITORS ON IN-HOSPITAL MORTALITY AFTER ACUTE ISCHEMIC STROKE

    Nov 1, 2010, 00:00

  • PIN2 ESTIMATED IMPACT OF SUSTAINED VIROLOGICAL RESPONSE (SVR) ON LIFE EXPECTANCY, QUALITY-ADJUSTED LIFE-YEARS (QALYS) AND LIFETIME COSTS IN CHRONIC HEPATITIS C (CHC) PATIENTS

    Nov 1, 2010, 00:00

  • PCV23 EVALUATING THE BENEFITS WITH TELECARE AMONG RESIDENTS IN NURSING HOMES IN TAIWAN

    Nov 1, 2010, 00:00

  • PCN2 PALONOSETRON VERSUS OTHER 5-HT3-RECEPTOR ANTAGONISTS IN PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENTS WITH CANCER TREATED IN A HOSPITAL OUTPATIENT SETTING

    Nov 1, 2010, 00:00

  • PMS51 PATIENT PREFERENCES FOR SEVERE OSTHEOPOROSIS IN SPAIN- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2010, 00:00

  • PDB34 THE ECONOMIC VALUE OF THE EASYPOD ELECTRONIC AUTOINJECTOR IN IMPROVING THE RESPONSE TO GROWTH HORMONE (GH) IN CHILDREN WITH IDIOPATHIC GROWTH HORMONE DEFICIENCY (IGHD)- A COST-CONSEQUENCE ANALYSIS

    Nov 1, 2010, 00:00

  • PND37 PATIENT AND PHYSICIAN GLOBAL PERCEPTION OF LEVODOPA/ CARBIDOPA/ENTACAPONE VS. LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING EARLY WEARING-OFF

    Nov 1, 2010, 00:00

  • PCN89 PROJECTING THE POTENTIAL COST-EFFECTIVENESS OF A BREAST CANCER VACCINE IN COMPARISON TO OTHER STANDARD TREATMENTS- A DECISION ANALYTIC MODEL

    Nov 1, 2010, 00:00

  • PCV38 CLINICAL AND ECONOMICAL BENEFITS OF THE USE OF REMOTE MONITORING WITH CARELINK IN CENTRO MDICO NACIONAL 'LA RAZA', IMSS MEXICO

    Nov 1, 2010, 00:00

  • HT1 EARLY ALERT SYSTEMS FOR NEW PHARMACEUTICALS-DO THEY HAVE AN IMPACT ON PHARMACEUTICAL REIMBURSEMENT DECISIONS?- A CROSS-NATIONAL COMPARISON

    Nov 1, 2010, 00:00

  • PMH58 MODELING PROGRESSION IN DEMENTIA- ASSESSING THE PERFORMANCE OF FIVE CLINICAL MEASURES IN SPANISH SUBJECTS AND CAREGIVERS

    Nov 1, 2010, 00:00

  • PMH1 METABOLIC SYNDROME AND SECOND GENERATION ANTIPSYCHOTICS UTILIZATION-IMPACT OF PSYCHIATRIC COMORBIDITY AND POLYPHARMACY

    Nov 1, 2010, 00:00

  • PCV87 USING VALUE OF INFORMATION ANALYSIS IN COMBINATION WITH AN EARLY STAGE MODEL OF COREVALVE FOR SEVERE AORTIC STENOSIS TO INFORM FUTURE RESEARCH NEEDS

    Nov 1, 2010, 00:00

  • PMS45 PRODUCTIVITY COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SOUTH KOREA

    Nov 1, 2010, 00:00

  • PMS6 COMPARISON OF RECENTLY REGISTERED BIOLOGICAL DRUGS WITH AVAILABLE THERAPIES IN RHEUMATOID ARTHRITIS- METHODOLOGICAL ISSUES TO CONSIDER FOR META-ANALYSIS

    Nov 1, 2010, 00:00

  • PSY31 POSACONAZOLE VS. FLUCONAZOLE OR ITRACONAZOLE FOR THE PREVENTION OF FUNGAL INFECTIONS IN CANCER PATIENTS WITH PROLONGED NEUTROPENIA- A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2010, 00:00

  • PCN21 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT HORMONAL TREATMENTS FOR POSTMENOPAUSAL HORMONE-RECEPTOR POSITIVE EARLY BREAST CANCER IN KOREAN CONTEXT

    Nov 1, 2010, 00:00

  • DS4 HERBAL PRODUCTS SAFETY- AN APPLICATION OF HEALTH PRODUCT VIGILANCE CENTER DATABASE

    Nov 1, 2010, 00:00

  • PSS27 COSMETI QOL-A TOOL FOR ASSESSING QUALITY OF LIFE IN COSMETIC DERMATOLOGY

    Nov 1, 2010, 00:00

  • HE3 ANALYSIS OF AN AFFORDABLE PRICE FOR PERFORMANCE-BASED RISK SHARING SCHEME- OMALIZUMAB ADAPTATION IN KOREA

    Nov 1, 2010, 00:00

  • PCV44 EVALUATION OF CLINICAL AND DIRECT ECONOMIC OUTCOMES BETWEEN STATIN AND FENOFIBRATE AND STATIN MONOTHERAPY FOLLOWING AN INITIAL ACUTE CORONARY EVENT

    Nov 1, 2010, 00:00

  • PHP62 VALUE OF CONGRESS ABSTRACTS OF COST-EFFECTIVENESS STUDIES FOR DECISION MAKERS

    Nov 1, 2010, 00:00

  • DU2 THE UTILIZATION OF PROPHYLACTIC ANTITHROMBOTIC AGENTS AFTER MAJOR ORTHOPEDIC SURGERIES-A POPULATION-BASED STUDY IN TAIWAN

    Nov 1, 2010, 00:00

  • PIH1 CRITICAL APPRAISAL OF SYSTEMATIC REVIEWS ASSESSING SAFETY OUTCOMES OF SSRIS IN THE PERINATAL PERIOD

    Nov 1, 2010, 00:00

  • PIH30 PERSISTENCE TO POSTMENOPAUSAL OSTEOPOROSIS (PMO) TREATMENTS IN A REGION OF SPAIN

    Nov 1, 2010, 00:00

  • PDB23 THE EFFECT OF METFORMIN BRAND SHIFT BY HOSPITAL ON DIABETIC TREATMENT OUTCOMES

    Nov 1, 2010, 00:00

  • PIH26 DEVELOPMENT OF A SEGMENTATION MODEL TO IDENTIFY HEALTH CARE DEMAND AND RELATED COSTS ATTRIBUTABLE TO POPULATIONS CHARACTERISTICS

    Nov 1, 2010, 00:00

  • PIN21 EMPIRIC ANTIBIOTIC PRRESCRIBING IN SUBJECTS WITH INFLUENZA IN A UNITED STATES COMMERCIALLY INSURED POPULATION

    Nov 1, 2010, 00:00

  • PIH34 DRUG COST REDUCTION IN LONG-TERM CARE PATIENTS WITH CHRONIC DISEASE

    Nov 1, 2010, 00:00

  • PIH3 A COSTING STUDY COMPARING MIDWIFERY GROUP PRACTICE WITH USUAL CARE IN AN AUSTRALIAN METROPOLITAN HOSPITAL

    Nov 1, 2010, 00:00

  • PIH35 DETERMINATION OF COMMUNITY PHARMACYS DISPENSING COST IN MALAYSIA

    Nov 1, 2010, 00:00

  • PMC17 ASSISTANCE COST DEPENDING ON COMORBIDITY IN PRIMARY CARE A SPANISH INTERREGIONAL LEVEL

    Nov 1, 2010, 00:00

  • RS2 PAYER ROADBLOCKS TO RISK-SHARING AGREEMENTS AROUND THE WORLD- WHERE, WHEN AND HOW?

    Nov 1, 2010, 00:00

  • PRS1 RISK OF SERIOUS ASTHMA EXACERBATIONS ASSOCIATED WITH LONG-ACTING-BETA-AGONISTS AMONG MEDICAID PATIENTS WITH ASTHMA-A RETROSPECTIVE COHORT STUDY

    Nov 1, 2010, 00:00

  • PND11 NURSE COSTING SURVEY FOR THE MANAGEMENT OF ADVERSE EVENTS IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH DISEASE-MODIFYING DRUGS IN THE UK

    Nov 1, 2010, 00:00

  • PCV139 INTEGRATING PATIENT PREFERENCES IN EFFICIENCY FRONTIER ANALYSES USING THE ANALYTIC HIERARCHY PROCESS

    Nov 1, 2010, 00:00

  • PMS26 HIP FRACTURES IN THE ELDERLY- COST OF ILLNESS STUDY UNDER A PUBLIC HOSPITAL PERSPECTIVE IN RIO DE JANEIRO, BRAZIL

    Nov 1, 2010, 00:00

  • PMS56 DETERMINING THE OPTIMAL TIMING FOR TOTAL KNEE REPLACEMENT

    Nov 1, 2010, 00:00

  • PIH30 THE DRINKING BEHAVIOR OF RESIDENTS OF A VILLAGE IN AN INDUSTRIAL PARK AREA-THE CURRENT SITUATION AND REASONS BEHIND THIS BEHAVIOR

    Nov 1, 2010, 00:00

  • PCN39 COST UTILITY OF HUMAN PAPILOMA VIRUS VACCINE IN SPAIN

    Nov 1, 2010, 00:00

  • PMS37 THE COST-EFFECTIVENESS OF ABATACEPT IN COMBINATION WITH METHOTREXATE FOR THE TREATMENT OF PATIENT WITH ACTIVE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PHP75 EVALUATION OF THE IMPACT OF INPATIENT CLINICAL PHARMACY SERVICES ON THE QUALITY AND COST OF PHARMACOTHERAPY IN INTERNAL MEDICINE WARDS

    Nov 1, 2010, 00:00

  • PMS7 A COST-EFFECTIVENESS ANALYSIS OF OSTEOPOROSIS TREATMENT FOR FRACTURE PREVENTION IN POSTMENOPAUSAL THAI WOMEN- A COMPARISON OF SEVEN TREATMENT OPTIONS

    Nov 1, 2010, 00:00

  • PIH38 EVALUATING THE HEALTH TECHNOLOGY ASSESSMENT PROGRAM IN THAILAND

    Nov 1, 2010, 00:00

  • CN1 EFFICACY OF THE COMBINATION BEVACIZUMAB PLUS CHEMOTHERAPY (BEV-CT) COMPARED TO CT ALONE IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)- SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)

    Nov 1, 2010, 00:00

  • PSS32 THE EXPERIENCE OF EXTERNAL GENITAL WARTS AND GENITAL HERPES ON QUALITY OF LIFE

    Nov 1, 2010, 00:00

  • PCN95 A MARKOV MODEL TO ESTIMATE THE COST-EFFECTIVENESS OF OMACETAXINE IN CHRONIC MYELOID LEUKEMIA

    Nov 1, 2010, 00:00

  • PMS63 THE IMPACT OF THE DRUG CATEGORIZATION ON THE PRESCRIPTION AND CONSUMPTION OF NONSTEROIDAL ANTIINFLAMATORY DRUGS (NSAID)

    Nov 1, 2010, 00:00

  • PUK12 THE ECONOMIC IMPACT OF RENAL GRAFT FAILURE-A COST ANALYSIS IN A UK SETTING

    Nov 1, 2010, 00:00

  • PMC46 TRANSLATION AND LINGUISTIC VALIDATION OF PRO MEASURES- RESPONSE OPTION ISSUES

    Nov 1, 2010, 00:00

  • PHP16 A COMPREHENSIVE STUDY OF GENERIC DRUG ENTRY IN THE UNITED STATES- 1991-2008

    Nov 1, 2010, 00:00

  • PHP66 AN ASSESSMENT OF THE VARIATION IN ACCEPTED ICERS BY DISEASE TYPE- RESULTS FROM FOUR HTAS

    Nov 1, 2010, 00:00

  • PMH52 A SHORT 12-ITEM ZARIT BURDEN INVENTORY FOR THE ASSESSMENT OF DEMENTIA CAREGIVERS AS OBTAINED BY ITEM RESPONSE THEORY

    Nov 1, 2010, 00:00

  • PMS18 A BUDGET IMPACT MODEL FOR THE ECONOMIC ASSESSMENT OF TOCILIZUMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS IN ITALY

    Nov 1, 2010, 00:00

  • PCV33 ESTIMATING THE FINANCIAL IMPLICATIONS TO THE UK NHS OF INTRODUCING COREVALVE ALONGSIDE MEDICAL MANAGEMENT FOR THE TREATMENT OF SEVERE AORTIC STENOSIS

    Nov 1, 2010, 00:00

  • PIH2 PEDIATRIC INTENSIVE CARE UNIT (PICU) ADMISSIONS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN THE ERA OF PALIVIZUMAB PROPHYLAXIS

    Nov 1, 2010, 00:00

  • PCV17 RESPONSE PROFILES OF SILDENAFIL CITRATE ON EXERCISE CAPACITY, HEMODYNAMIC FUNCTION, AND HEALTH-RELATED QUALITY OF LIFE IN CHILDREN WITH PULMONARY ARTERIAL HYPERTENSION

    Nov 1, 2010, 00:00

  • PSS10 CLINICAL AND COST-EFFECTIVENESS EVALUATION OF A LOW FRICTION AND SHEAR PRODUCT IN THE MANAGEMENT OF PATIENTS AT RISK OF SKIN BREAKDOWN WITHIN A HOSPITAL SETTING

    Nov 1, 2010, 00:00

  • PCV20 COMPLIANCE WITH ANTIHYPERTENSIVE AGENTS AND THE ONSET OF END-STAGE RENAL DISEASE

    Nov 1, 2010, 00:00

  • PCN145 INEQUALITIES IN GEOGRAPHICAL ACCESS TO ONCOLOGY SERVICES IN GREECE AND THEIR IMPACT ON PATIENTS AND CARERS

    Nov 1, 2010, 00:00

  • HT2 INFLUENCE OF HTA AND HOSPITAL FUNDING SYSTEMS ON PATIENT ACCESS TO INNOVATIVE MEDICINES- EXAMPLE OF ADVANCED RENAL CELL CANCER IN WESTERN EUROPE

    Nov 1, 2010, 00:00

  • PSY34 COST-EFFECTIVENESS OF TAPENTADOL PROLONGED-RELEASE (PR) COMPARED TO OXYCODONE AND MORPHINE IN PATIENTS WITH CHRONIC MODERATE TO SEVERE NON-CANCER PAIN IN SWEDEN

    Nov 1, 2010, 00:00

  • PHP50 FRAGMENTED HEALTH CARE SYSTEM-SOLVING THE JIGSAW PUZZLE

    Nov 1, 2010, 00:00

  • PIH66 IDENTIFYING APPROPRIATE COMPARISON GROUPS IN GLOBAL PREGNANCY REGISTRIES

    Nov 1, 2010, 00:00

  • CN1 CERVICAL CANCER SCREENING PROGRAM IN THAILAND- ASSESSMENT OF SERVICE COVERAGE AND DETERMINANTS OF PROGRAM UPTAKE

    Nov 1, 2010, 00:00

  • PCV28 HEALTH-RELATED QUALITY OF LIFE AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROMES

    Nov 1, 2010, 00:00

  • PSS3 EPIDEMIOLOGY, COSTS AND QUALITY OF LIFE IN PATIENT WITH SEVERE CHRONIC HAND ECZEMA

    Nov 1, 2010, 00:00

  • PCV97 AN EVALUATION OF ONCE- VERSUS TWICE-DAILY DOSING ON PERSISTENCE WITH PRESCRIPTION MEDICATIONS IN CARDIOVASCULAR PATIENTS

    Nov 1, 2010, 00:00

  • PMS31 THE IMPACT OF CHANGES IN ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB DOSES ON THE COSTS OF TREATING RHEUMATOID ARTHRITIS

    Nov 1, 2010, 00:00

  • PCV18 COMPARISON OF MIXED DYSLIPIDEMIAS AMONG HIGH CARDIOVASCULAR RISK PRIMARY CARE PATIENTS- RESULTS OF A POOLED ANALYSIS OF PRIMULA DATA FROM CANADA, SPAIN, SWEDEN, AND THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PCV46 A SURVEY EXPLORING KNOWLEDGE AND PERCEPTIONS OF GENERAL PRACTITIONERS TOWARD THE USE OF GENERIC MEDICINES IN THE NORTHERN STATE OF MALAYSIA

    Nov 1, 2010, 00:00

  • PUK4 A SYSTEMATIC REVIEW OF IMMUNOSUPPRESSIVE REGIMENS IN LOWER IMMUNOLOGICAL RISK RENAL TRANSPLANT RECIPIENTS

    Nov 1, 2010, 00:00

  • PCV79 COST-EFFECTIVENESS OF DRONEDARONE IN SOUTH KOREA

    Nov 1, 2010, 00:00

  • PSY42 COST-EFFECTIVENESS ANALYSIS OF BIOLOGICS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN THE PUBLIC HEALTH CARE SYSTEM OF BRAZIL

    Nov 1, 2010, 00:00

  • PCN15 SYSTEMATIC REVIEW OF LAPATINIB PLUS LETROZOLE WITH OTHER FIRST LINE TREATMENTS FOR HORMONE POSITIVE (HR ADVANCED OR METASTATIC BREAST CANCER (MBC)

    Nov 1, 2010, 00:00

  • PIN54 COST-EFFECTIVENESS ANALYSES (CEA) OF LOPINAVIR/RITONAVIR (LPV/R) AND ATAZANAVIR PLUS RITONAVIR (ATV VE HIV-1 INFECTED PATIENTS BASED ON CASTLE 48-WEEK STUDY- APPLICATION TO SWEDEN

    Nov 1, 2010, 00:00

  • PIH28 DETERMINANTS OF HEALTH SERVICE UTILIZATION FOLLOWING THE 2004 TSUNAMI IN THAILAND

    Nov 1, 2010, 00:00

  • PHP74 PRIMARY HEALTH CARE AND POTENTIALLY AVOIDABLE ADMISSIONS-A 10-YEAR ASSESSMENT FROM THE PERSPECTIVE OF A HEALTH CARE PLAN

    Nov 1, 2010, 00:00

  • PND25 ECONOMIC EVALUATION OF NATALIZUMAB IN THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN 4 EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PDB64 TREATMENT PERSISTENCE AMONG PATIENTS INITIATING INSULIN THERAPY WITH INSULIN DETEMIR IN A FLEXPEN VERSUS NPH INSULIN IN A VIAL. RETROSPECTIVE DATABASE ANALYSIS BASED ON A LARGE US MANAGED CARE ORGANIZATION

    Nov 1, 2010, 00:00

  • PCN120 UTILITY AND WORK PRODUCTIVITY DATA FOR ECONOMIC EVALUATION OF BREAST CANCER THERAPIES IN THE NETHERLANDS AND SWEDEN

    Nov 1, 2010, 00:00

  • PCN23 SIMULATION AND COMPARISON OF PROGRESSION-FREE-SURVIVAL OUTCOMES OF SEQUENTIAL TARGETED THERAPY IN METASTATIC RENAL-CELL CARCINOMA

    Nov 1, 2010, 00:00

  • PHP20 TRENDS IN DRUG EXPENDITURES IN SONGKHLA HOSPITAL

    Nov 1, 2010, 00:00

  • PIH56 COMPARATIVE PRICING AND REIMBURSEMENT ANALYSIS BETWEEN BULGARIA AND THE CZECH REPUBLIC

    Nov 1, 2010, 00:00

  • PDB72 FURTHER DEVELOPMENTS OF THE QUALITY OF LIFE ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA)

    Nov 1, 2010, 00:00

  • PMC25 STATISTICAL DISTRIBUTIONS OF COST DATA IN PROBABILISTIC SENSITIVITY ANALYSIS

    Nov 1, 2010, 00:00

  • PRS29 COST-EFFECTIVENESS OF SALMETEROL/FLUTICASONE PROPIONATE COMBINATION VERSUS LEUKOTRIENE MONTELUKAST FOR THE CONTROL OF PERSISTENT ASTHMA IN CHILDREN

    Nov 1, 2010, 00:00

  • PHP26 DEVELOPMENT OF SYSTEMATIC PROCESS MAPS TO ENABLE COMPARISON BETWEEN DIFFERENT HTA AND DECISION MAKING SYSTEMS-THE FIRST STEP TO BENCHMARKING

    Nov 1, 2010, 00:00

  • PCV3 MIXED TREATMENT COMPARISON OF PROPHYLAXIS REGIMENS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN TOTAL HIP REPLACEMENT, HIP FRACTURE, TOTAL KNEE REPLACEMENT AND GENERAL SURGERY

    Nov 1, 2010, 00:00

  • PCV130 PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2008-2009- BASELINE RESULTS FOR AUSTRIA FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II)

    Nov 1, 2010, 00:00

  • PSS13 COSTS AND EFFECTS OF FIXED COMBINATION THERAPIES IN OPEN ANGLE GLAUCOMA

    Nov 1, 2010, 00:00

  • PCN64 SURVEY AND ANALYSIS OF THE COST OF METASTATIC COLORECTAL CANCER TREATMENT IN SLOVENIA

    Nov 1, 2010, 00:00

  • PMC43 DATA POOLING OF PATIENT-REPORTED OUTCOMES IN CLINICAL TRIALS- EVALUATION OF STATISTICAL TECHNIQUES FOR ASSESSING MEASUREMENT EQUIVALENCE

    Nov 1, 2010, 00:00

  • PMS12 PROJECTION OF SURGICAL LOADS OF HIP AND KNEE

    Nov 1, 2010, 00:00

  • PSY21 THE IMPACT OF COMORBIDITY ON INFLAMMATORY BOWEL DISEASE HEALTH COSTS

    Nov 1, 2010, 00:00

  • PND1 OUTCOME OF PHARMACIST INTERVENTION IN EDUCATION OF PATIENTS ON DUPLICATE PRESCRIPING HYPNOTIC-SEDATIVES

    Nov 1, 2010, 00:00

  • PSS21 AN ECONOMIC ANALYSIS OF TACROLIMUS OINTMENT MAINTENANCE USE (TWICE WEEKLY) VERSUS STANDARD USE IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS IN NORWAY AND FINLAND

    Nov 1, 2010, 00:00

  • PHP87 THE ROLE OF VALUE OF INFORMATION ANALYSIS IN HEALTH CARE RESEARCH PRIORITY SETTING-A THEORETICAL CASE STUDY

    Nov 1, 2010, 00:00

  • PND13 A PROSPECTIVE STUDY OF THE FINANCIAL COSTS OF MULTIPLE SCLEROSIS AT DIFFERENT STAGES OF THE ILLNESS IN IRAN

    Nov 1, 2010, 00:00

  • BI4 ARE SECOND OPINIONS OBJECTIVE? BIASES IN SECOND-OPINION CONSULTATIONS

    Nov 1, 2010, 00:00

  • PHP30 MARKET ACCESS, AFFORDABILITY AND PRICE COMPONENTS OF MEDICINES IN THE UNITED ARAB EMIRATES (UAE)

    Nov 1, 2010, 00:00

  • PHP86 SUCCESSFUL IMPLEMENTATION OF COVERAGE WITH EVIDENCE DEVELOPMENT SCHEMES- PRACTICAL EXPERIENCES IN SEVERAL WESTERN JURISDICTIONS

    Nov 1, 2010, 00:00

  • PCN165 INFLATION ANALYSIS AS A TOOL TO ASSESS COST-EFFECTIVENESS OF CANCER TREATMENT

    Nov 1, 2010, 00:00

  • PDB62 COST-UTILITY ANALYSIS OF SAXAGLIPTIN AS AN ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES PATIENTS FROM THE BRAZILIAN PRIVATE HEALTH SYSTEM

    Nov 1, 2010, 00:00

  • PRS43 COMPLIANCE TO GOLD GUIDELINES IN THE TREATMENT OF COPD- APPROPRIATENESS AND POTENTIAL COST SAVING IN ITALY

    Nov 1, 2010, 00:00

  • PHP130 TRENDS IN COST CONTAINMENT MEASURES

    Nov 1, 2010, 00:00

  • PCN133 EPICLIN-LUNG STUDY- NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENT QUALITY OF LIFE AND HEALTH-STATE ASSESSMENT

    Nov 1, 2010, 00:00

  • PHP38 COMPLEXITY INCREASES UNCERTAINTY-THE IMPACT OF PBAC GUIDELINES (VERSION 4) ON PBAC DECISION-MAKING

    Nov 1, 2010, 00:00

  • PCN132 ERLOTINIB MAINTENANCE THERAPY FOR NON-SMALL CELL LUNG CANCER PRESERVES QUALITY OF LIFE

    Nov 1, 2010, 00:00

  • PCV76 COST-EFFECTIVENESS ANALYSIS OF DRONEDARONE IN PATIENTS WITH ATRIAL FIBRILLATION IN MEXICO- A WITHIN TRIAL ANALYSIS BASED ON ATHENA TRIAL

    Nov 1, 2010, 00:00

  • PHP44 APPLICATION OF PERATOS PRINCIPLE TO UNDERSTAND COST DRIVERS IN HEALTH CARE

    Nov 1, 2010, 00:00

  • PIN42 THE COST-EFFECTIVENESS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) COMPARED WITH 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV10) IN TAIWAN

    Nov 1, 2010, 00:00

  • PHP6 ROUTINE OF PATIENTS REDIRECTION IN THE HUNGARIAN PRIMARY CARE

    Nov 1, 2010, 00:00

  • PCN25 COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL AS A SECOND- OR THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN KOREA

    Nov 1, 2010, 00:00

  • PIH19 ETHNIC/RACIAL DIFFERENCE IN SELF-ASSESSMENT OF HEALTH STATUS IN THE GENERAL US POPULATION

    Nov 1, 2010, 00:00

  • PND40 QUALITY OF LIFE OF CAREGIVERS IN HUNTINGTONS DISEASE-FIRST RESULTS FROM EURO-HDB STUDY

    Nov 1, 2010, 00:00

  • PCV39 DOSE STATIN USE IN PATIENTS WITH DIABETES SAVE DOWNSTREAM RESOURCE UTILIZATION? A DIFFERENCE-IN DIFFERENCES ANALYSIS

    Nov 1, 2010, 00:00

  • PIN53 COST-UTILITY ANALYSIS OF NEW PNEUMOCOCCAL CONJUGATE VACCINES IN THE REGIONAL IMMUNIZATION PROGRAM OF THE AUTONOMOUS REGION OF MADRID-IMPACT ON INVASIVE PNEUMOCOCCAL DISEASE

    Nov 1, 2010, 00:00

  • PSY60 RESULTS FROM A COMPREHENSIVE LITERATURE REVIEW OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)- MORE RESEARCH IS NEEDED?

    Nov 1, 2010, 00:00

  • PCN79 ECONOMIC MODELING FOR TREATMENT FAILURE PATIENTS USING MULTIPLE ROUNDS OF THERAPY AS COMPARATOR

    Nov 1, 2010, 00:00

  • PCV27 INCREASING PREVALENCE OF HYPERTENSION IN NIGERIA-A SYSTEMATIC REVIEW FROM 1990 TO 2009

    Nov 1, 2010, 00:00

  • PHP96 SENSE OF COHERENCE-AS MEDIATING FACTOR IN REMAINING EMPLOYED IN HEALTH CARE PROFESSION

    Nov 1, 2010, 00:00

  • PCN47 CHANGE OF ANTIFUNGAL TREATMENT PATTERNS AND ASSOCIATED COSTS IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) AFTER CHEMOTHERAPY IN A GERMAN HOSPITAL FROM 2004 TO 2006

    Nov 1, 2010, 00:00

  • PIN43 A COST-EFFECTIVENESS ANALYSIS OF ANTIMICROBIAL THERAPY OF BLOODSTREAM INFECTIONS TREATMENT IN INTENSIVE CARE UNIT

    Nov 1, 2010, 00:00

  • PHP72 ANALYSIS THE AVERAGE SOJOURN TIME AND BOTTLENECK AFTER A DISASTER IN HOSPITALS

    Nov 1, 2010, 00:00

  • PUK7 THE PHARMACY BUDGET IMPACT OF EXTENDING REIMBURSEMENT OF LANTHANUM CARBONATE TO TREATMENT OF HYPERPHOSPHATEMIA (1.78 MMOL/L) IN PATIENTS WITH CHRONIC KIDNEY DISEASE PRE-DIALYSIS IN FRANCE AND THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PIN73 FACTORS AFFECTING THE DECISION TO RECEIVE VACCINATION FOR INFLUENZA VIRUS H1N1

    Nov 1, 2010, 00:00

  • PDB18 THE PREVALENCE AND IMPACT OF BEING AT-RISK FOR DIABETES ACROSS US, JAPAN, AND EUROPE

    Nov 1, 2010, 00:00

  • PIH7 ECONOMIC EVALUATION OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATIONS IN THE PREVENTION OF CERVICAL CANCER

    Nov 1, 2010, 00:00

  • PND18 48-HOUR INFUSION OF METHYLPREDNISOLONE IS A COST-EFFECTIVE INTERVENTION FOR TRAUMATIC SPINAL CORD INJURY

    Nov 1, 2010, 00:00

  • PRS32 REGIONAL DIFFERENCES AS A BASIS FOR SENSITIVITY ANALYSIS OF COST-EFFECTIVENESS OF SALMETEROL FLUTICASONE PROPIONATE (SAL/FP) VS. INHALED CORTICOSTEROIDS (MONO-ICS)

    Nov 1, 2010, 00:00

  • PIN9 EFFICACY AND SAFETY OF RALTEGRAVIR IN TREATMENT NAIVE HIV PATIENTS-A MIXED TREATMENT COMPARISON APPROACH

    Nov 1, 2010, 00:00

  • PSS7 THE ECONOMIC COST OF TREATING PATIENTS WITH AGE-RELATED MACULAR DEGENERATION IN SPAIN

    Nov 1, 2010, 00:00

  • PHP126 PATIENT ACCESS SCHEMES (PAS) IN THE UK COMING OF AGE-WHAT IMPACT WILL THEY HAVE ON OTHER EU COUNTRIES LIKE ITALY?

    Nov 1, 2010, 00:00

  • PIH65 USING A GENERALIZED ADDITIVE MODEL TO EXAMINE THE RELATIONSHIP BETWEEN BODY MASS INDEX AND HEALTH-RELATED QUALITY OF LIFE IN THE ELDERLY POPULATION-RESULTS FROM THE POPULATION-BASED GERMAN KORA-AGE STUDY

    Nov 1, 2010, 00:00

  • PMH2 COMPARING ALL-CAUSE MEDICATION DISCONTINUATION WITH DEPOT AND ORAL ANTIPSYCHOTICS IN MATCHED COHORTS OF PATIENTS WITH SCHIZOPHRENIA- A 12-MONTH OBSERVATIONAL STUDY

    Nov 1, 2010, 00:00

  • PCV11 PLATELET FUNCTION TESTS ARE HIGHLY VARIABLE WHEN USED TO IDENTIFY PATIENTS RESISTANT TO CLOPIDOGREL

    Nov 1, 2010, 00:00

  • PUK6 POST RENAL TRANSPLANT PATIENT SURVIVAL AND THE COMBINED ADVERSE EFFECT OF POOR RENAL FUNCTION AND NEW ONSET DIABETES MELLITUS

    Nov 1, 2010, 00:00

  • PCV61 ECONOMICS ESTIMATION OF SIDE EFFECTS CORRECTION ANTIHYPERTENSIVE MEDICAL PRODUCTS OF INHIBITORS-ACE IN RUSSIAN HEALTH

    Nov 1, 2010, 00:00

  • PMS16 EARLY MORTALITY RATE OF BILATERAL HIP FRACTURES OVER 60 IN HUNGARY

    Nov 1, 2010, 00:00

  • PMH16 THE ECONOMIC AND HUMANISTIC BURDEN OF ILLNESS IN GENERALISED ANXIETY DISORDER (GAD)- A RETROSPECTIVE DATABASE ANALYSIS IN EUROPE

    Nov 1, 2010, 00:00

  • PCN20 MAINTENANCE ERLOTINIB VERSUS PEMETREXED FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER- INDIRECT COMPARISON APPLYING REAL-LIFE OUTCOMES

    Nov 1, 2010, 00:00

  • PDB70 MEASUREMENT OF HRQOL USING EQ-5D IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH ORAL ANTI-DIABETIC DRUGS IN CHINA

    Nov 1, 2010, 00:00

  • PRS24 LONG-TERM EFFECTIVENESS AND COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS IN PATIENTS WITH COPD

    Nov 1, 2010, 00:00

  • PSS30 DISCREPANCY IN PATIENT AND PHYSICIAN GLOBAL ASSESSMENTS OF DERMATOLOGIC DISEASES

    Nov 1, 2010, 00:00

  • PIH6 IMPACT OF ROTAVIRUS VACCINATION ON ACUTE GASTROENTERITIS RELATED EMERGENCY ROOM VISITS IN CHILDREN FIVE YEARS OLD IN BELGIUM

    Nov 1, 2010, 00:00

  • PDB46 COST-EFFECTIVENESS OF NEW ANTIDIABETICS IN TYPE 2 DIABETES- A REVIEW

    Nov 1, 2010, 00:00

  • CV4 THE CLINICAL EFFECTIVENESS OF 64-SLICE OR HIGHER COMPUTED TOMOGRAPHY ANGIOGRAPHY AS AN ALTERNATIVE TO INVASIVE CORONARY ANGIOGRAPHY IN THE INVESTIGATION OF SUSPECTED CORONARY ARTERY DISEASE

    Nov 1, 2010, 00:00

  • PCN53 ANALYSIS OF SOCIOECONOMIC BUREDN OF HEPATOCELLULAR CARCINOMA IN RUSSIA

    Nov 1, 2010, 00:00

  • PMC18 MULTI-NATIONAL CHART REVIEW STUDIES IN EUROPE- OPPORTUNITIES AND CHALLENGES

    Nov 1, 2010, 00:00

  • PMS3 THE RISK OF REFRACTURE ASSOCIATED WITH THE COMPLIANCE AND THE PERSISTENCE WITH BISPHOSPHONATE THERAPY IN TAIWAN

    Nov 1, 2010, 00:00

  • PMC14 DISCOUNTING HEALTH EFFECTS- A REVIEW OF THE SYSTEM

    Nov 1, 2010, 00:00

  • PDB44 THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY

    Nov 1, 2010, 00:00

  • PIH45 HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF FERTILE WOMEN USERS OF CONTRACEPTIVE METHODS

    Nov 1, 2010, 00:00

  • PCV29 PREVALENCE, CHARACTERISTICS, AND IN-HOSPITAL OUTCOMES OF METABOLIC SYNDROME IN ACUTE CORONARY DISEASE PATIENTS IN OMAN

    Nov 1, 2010, 00:00

  • PIN24 IMPACT OF APPROPRIATE PRESCRIBING OF ANTIBIOTICS ON TREATMENT OUTCOMES, DAYS OF PATIENT HOSPITALIZATION AND COSTS OF ANTIBIOTIC TREATMENT IN HOSPITALS IN LESOTHO

    Nov 1, 2010, 00:00

  • PMH14 ADHERENCE AND PERSISTENCE WITH DULOXETINE VERSUS ESCITALOPRAM AMONG HIGH HEALTH-CARE RESOURCES UTILIZERS WITH MAJOR DEPRESSIVE DISORDER

    Nov 1, 2010, 00:00

  • PHP13 IMPLEMENTATION OF THE TRANSPARENCY DIRECTIVE IN HUNGARY

    Nov 1, 2010, 00:00

  • PHP4 POST HEALTH CARE REFORM PERCEPTIONS IN THE US- CONSUMER PULSE SURVEY

    Nov 1, 2010, 00:00

  • PMH70 TURKISH CULTURAL ADAPTATION AND VALIDATION OF THE ALCOHOL DEPENDENCE SCALE

    Nov 1, 2010, 00:00

  • PCV90 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS SIMVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK-A SWEDISH ECONOMIC EVALUATION BASED UPON THE JUPITER TRIAL

    Nov 1, 2010, 00:00

  • PMS57 HEALTH-RELATED QUALITY OF LIFE AFTER TOTAL KNEE REPLACEMENT OR UNICOMPARTMENTAL KNEE ARTHROPLASTY IN AN URBAN ASIAN POPULATION

    Nov 1, 2010, 00:00

  • PCN147 MEDICAL RESOURCES UTILIZATION OF FIVE MOST PREVALENT CANCERS IN TAIWAN (LUNG CANCER, LIVER CANCER, COLORECTAL CANCER, GASTRIC CANCER, AND BREST CANCER)- 2001~2007

    Nov 1, 2010, 00:00

  • PIN15 COST-EFFECTIVENESS ANALYSIS OF 1-YEAR PEGINTERFERON ALFA-2A VERSUS 3 YEARS ENTECAVIR FOR THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B IN CHINA

    Nov 1, 2010, 00:00

  • PCV63 COST OF ABLATION PROCEDURES FOR ATRIAL FIBRILLATION- RESULTS FROM THE AIAC SURVEY

    Nov 1, 2010, 00:00

  • PCV47 A NATIONAL SURVEY OF SOCIETAL COST OF ACUTE CORONARY SYNDROME IN SOUTH KOREA

    Nov 1, 2010, 00:00

  • HT2 COST-EFFECTIVENESS OF INTERVENTIONS FOR REDUCING ROAD TRAFFIC INJURIES RELATED TO DRIVING UNDER THE INFLUENCE OF ALCOHOL

    Nov 1, 2010, 00:00

  • PCN98 COST-EFFECTIVENESS OF A EUROPEAN COMMUNITY-BASED INTERVENTION- '10,000 STEPS GHENT'

    Nov 1, 2010, 00:00

  • PCN106 INDIRECT COST IN NON-SMALL CELL LUNG CANCER (NSCLC)- A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2010, 00:00

  • PCN21 FIRST-LINE BEVACIZUMAB-BASED THERAPY VERSUS PEMETREXED CISPLATIN FOR THE TREATMENT OF ADVANCED ADENOCARCINOMA NONSQUAMOUS NON-SMALL CELL LUNG CANCER- INDIRECT COMPARISON APPLYING REAL-LIFE OUTCOMES

    Nov 1, 2010, 00:00

  • PIN76 THE USE OF ECONOMIC ANALYSIS IN VACCINE EXPERT REVIEWS

    Nov 1, 2010, 00:00

  • PMH41 COST-UTILITY ANALYSIS OF ESCITALOPRAM VERSUS CITALOPRAM IN MAJOR DEPRESSIVE DISORDER IN ISRAEL

    Nov 1, 2010, 00:00

  • PIH35 DEMONSTRATING CONCEPTUAL EQUIVALENCE ACROSS MULTIPLE CULTURES- TRANSLATION AND LINGUISTIC VALIDATION OF THE IPAQ

    Nov 1, 2010, 00:00

  • PCN35 CLINICAL AND ECONOMIC IMPLICATIONS OF SCREENING FOR KRAS MUTATIONS IN METASTATIC COLORECTAL CANCER PATIENTS IN SPAIN- A COST-EFFECTIVENESS AND BUDGET IMPACT MODEL

    Nov 1, 2010, 00:00

  • PIN50 COST-EFFECTIVENESS OF PEGINTERFERON ALPHA-2A VERSUS PEGINTERFERON ALPHA-2B FOR TREATMENT OF CHRONIC HEPATTIS C INFECTION IN MEXICO

    Nov 1, 2010, 00:00

  • PCV129 TELEHEALTH-EARLY EVALUATION FINDINGS

    Nov 1, 2010, 00:00

  • PCN48 COST-EFFECTIVENESS COMPARISON OF APPROACHES FOR LOW-RISK PROSTATE CANCER CARE-THE NEED TO BALANCE COST AND UTILITY

    Nov 1, 2010, 00:00

  • PDB2 LONG-TERM HEALTH OUTCOMES OF TREATMENT WITH LIRAGLUTIDE VERSUS GLIMEPRIRIDE IN TYPE 2 DIABETES PATIENTS IN ASIAN SETTING

    Nov 1, 2010, 00:00

  • PSY2 THE USE OF ETANERCEPT FOR TREATMENT OF PSORIASIS IN REAL CLINICAL PRACTICE-NON-INTERVENTION OBSERVATIONAL STUDY

    Nov 1, 2010, 00:00

  • PCV41 COST COMPARISON STUDY IN ACUTE CORONARY SYNDROMES AND ACUTE HEART FAILURE PATIENTS

    Nov 1, 2010, 00:00

  • PCN151 TARGETED CANCER THERAPIES- PRICING, ACCESS, AND UPTAKE

    Nov 1, 2010, 00:00

  • PIN20 PSEUDOMONAS AERUGINOSA RELATED ECONOMIC BURDEN STRATIFIED BY COMORBIDITY IN CYSTIC FIBROSIS PATIENTS

    Nov 1, 2010, 00:00

  • PHP92 COST-EFFECTIVENESS OF KNOWLEDGE TRANSLATION METHODS

    Nov 1, 2010, 00:00

  • PIH52 EVALUATING THE PERCEPTION OF HOSPITAL PHARMACIST TOWARD THEIR CURRENT CLINICAL ROLE IN HEALTH CARE SYSTEM OF PAKISTAN

    Nov 1, 2010, 00:00

  • PCN50 BURDEN OF HOSPITALIZATIONS FOR HEPATOCELLULAR CARCINOMA PATIENTS IN A US POPULATION

    Nov 1, 2010, 00:00

  • PDB20 OLDER WOMEN WITH DIABETES- CARDIOVASCULAR MEDICATION USE AND QUALITY OF LIFE

    Nov 1, 2010, 00:00

  • PMC51 CONCEPT ELABORATION-AN ESSENTIAL STAGE IN THE TRANSLATION OF PRO MEASURES

    Nov 1, 2010, 00:00

  • PUK30 MAPPING THE OVERACTIVE BLADDER QUESTIONNAIRE-SHORT FORM (OABQ-SF) TO EQ-5D PATIENT PREFERENCES IN PATIENTS WITH OVERACTIVE BLADDER IN SPAIN

    Nov 1, 2010, 00:00

  • PCV22 THE INFLUENCE OF METEOROLOGICAL FACTORS ON CEREBRAL INFARCTION, INTRACEREBRAL HEMORRHAGE, SUBARACHNOID HEMORRHAGE AND TRANSIENT ISCHEMIC ATTACK

    Nov 1, 2010, 00:00

  • PIN67 MODELING G-DRG REVENUE WHEN HOSPITALIZATION DURATION FROM CLINICAL TRIALS IS AVAILABLE-THE CASE OF DORIPENEM VERSUS IMIPENEM IN TREATING VENTILATOR-ASSOCIATED PNEUMONIA (VAP) IN GERMANY

    Nov 1, 2010, 00:00

  • ME1 METHODOLOGICAL ISSUES IN THE DEVELOPMENT OF AN AUSTRALIAN ALGORITHM FOR THE EQ-5D

    Nov 1, 2010, 00:00

  • PIN28 IMPACT OF METHODOLOGICAL CHOICES AND ASSUMPTIONS IN ECONOMIC EVALUATIONS OF ROTAVIRUS VACCINATION

    Nov 1, 2010, 00:00

  • PUK27 TIME SAVINGS WITH Q4W (ONCE-MONTHLY) C.E.R.A.- A TIME AND MOTION STUDY CONDUCTED IN HEMODIALYSIS CENTRES IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PMC61 MONITORING OF HEALTH ECONOMIC DATA IN CLINICAL TRIALS

    Nov 1, 2010, 00:00

  • PRS10 TRENDS IN ANTI-ASTHMA MEDICATION USE IN DUTCH CHILDREN FROM 1998 UNTIL 2007

    Nov 1, 2010, 00:00

  • PCN24 EFFICACY OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE (GEM) COMPARED TO SURGERY-ONLY IN PATIENTS WITH RESECTED PANCREATIC CANCER- SYSTEMATIC REVIEW (SR) AND METAANALYSIS (MA)

    Nov 1, 2010, 00:00

  • PHP94 IS IT COST-EFFECTIVE TO CHANGE THE BEHAVIOR OF HEALTH CARE PROFESSIONALS?

    Nov 1, 2010, 00:00

  • PSY64 SEQUENCE OF TREATMENT IN IMMUNE THROMBOCYTOPENIA (ITP) PATIENTS- RESULTS OF A MEDICAL RECORD REVIEW FROM EIGHT HOSPITALS IN SPAIN

    Nov 1, 2010, 00:00

  • PDB81 TIME TO ADD-ON MEDICATION USE FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WHO FAILED METFORMIN MONOTHERAPY

    Nov 1, 2010, 00:00

  • PDB13 DIAPS 79, PRELIMINARY REPORT OF AN OBSERVATIONAL STUDY OF COSTS OF TYPE 2 DIABETES MELLITUS (T2DM) TREATMENT IN THE BRAZILIAN PRIVATE HEALTH-CARE SYSTEM (PHS)

    Nov 1, 2010, 00:00

  • PSY4 BIOLOGICAL AGENTS FOR THE TREATMENT OF NAIL PSORIASIS- A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2010, 00:00

  • PIN16 HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH HEPATITIS A IN A US COMMERCIALLY INSURED POPULATION

    Nov 1, 2010, 00:00

  • PIH8 ESTIMATED HEALTH AND ECONOMIC IMPACT OF QUADRIVALENT HPV TYPES 6, 11, 16, 18 VACCINE IN THAILAND USING A TRANSMISSION DYNAMIC MODEL

    Nov 1, 2010, 00:00

  • PGI31 EVALUATING THE POST OPERATIVE PRESCRIBING PRACTICES FOR APPENDICITIS IN PUBLIC HEALTH FACILITIES IN PAKISTAN

    Nov 1, 2010, 00:00

  • PDB6 PERFORMANCES OF COMORBIDITY MEASURES IN HEALTH CARERELATED BEHAVIORS AND OUTCOMES IN TYPE 2 DIABETES

    Nov 1, 2010, 00:00

  • PND5 BUDGET-IMPACT MODEL TO TEST EFFECTS OF CHANGING RUFINAMIDE TIER STATUS FROM A PAYER PERSPECTIVE

    Nov 1, 2010, 00:00

  • NI4 DO PATIENT ACCESS SCHEMES RESULT IN AN ACCEPTABLE ADMINISTRATIVE BURDEN?

    Nov 1, 2010, 00:00

  • PND9 ASSESSMENT OF DISEASE BURDEN ASSOCIATED WITH EPILEPSY IN HUNGARY, BASED ON A CROSS-SECTIONAL QUESTIONNAIRE SURVEY OF 100 PATIENTS

    Nov 1, 2010, 00:00

  • PHP107 ECONOMIC EVIDENCE REQUIREMENTS- COMPARISON BETWEEN HTA AGENCIES AND IMPLICATIONS FOR MANUFACTURERS

    Nov 1, 2010, 00:00

  • PRS5 BUDESONIDE/FORMOTEROL PLUS TIOTROPIUM (BUD/FORM TIO)- A SYSTEMATIC REVIEW AND ADJUSTED INDIRECT COMPARISON BETWEEN TWO ALTERNATIVE TRIPLE TREATMENTS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2010, 00:00

  • PHP112 ANALYSIS OF PHARMACISTS INTERVENTIONS OF ELECTRONIC PRESCRIPTIONS AT SULTAN QABOOS UNIVERSITY HOSPITAL IN OMAN

    Nov 1, 2010, 00:00

  • PRS4 EFFECTIVENESS OF VARENICLINE COMPARED TO BUPROPION AND NICOTINE REPLACEMENT THERAPY (NRT) FOR SMOKING CESSATION IN TWO SMOKING SPECIALIZED UNITS OF THE SPANISH PRIMARY CARE SETTING

    Nov 1, 2010, 00:00

  • PIN69 OUTPATIENT ANTIBIOTIC USE IN PRIMARY HEALTH CARE IN NIS REGION

    Nov 1, 2010, 00:00

  • PHP127 ADOPTING A FINANCIAL RISK-SHARING SCHEME FOR NEW TECHNOLOGIES ADDED TO THE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL- STAKEHOLDERS STATED INCENTIVES AND DISINCENTIVES

    Nov 1, 2010, 00:00

  • PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT ELDERLY PATIENTS- AN ECONOMICAL ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY (GFPC 0504)

    Nov 1, 2010, 00:00

  • PCV1 ESTIMATION OF STROKE-RELATED ADVERSE EVENTS, HEALTH CARE UTILITY AND COST OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

    Nov 1, 2010, 00:00

  • PHP103 NICE GUIDANCE-AN ANALYSIS OF LEVELS OF RESTRICTION BY DISEASE AREA

    Nov 1, 2010, 00:00

  • PMC1 BEST PRACTICES IN REPORTING OF PROSPECTIVE OBSERVATIONAL STUDIES

    Nov 1, 2010, 00:00

  • PND44 HEALTH RELATED QUALITY OF LIFE DEFICITS IN MULTIPLE SCLEROSIS-A POPULATION CONTROL ANALYSIS

    Nov 1, 2010, 00:00

  • PRS41 FACTORS AFFECTING QUALITY OF LIFE (QOL) OF ASTHMATIC PATIENTS IN SPAIN

    Nov 1, 2010, 00:00

  • PGI2 A SYSTEMATIC REVIEW AND META-ANALYSIS OF LITERATURE ASSESSING CLINICAL EFFICACY OF TREATMENTS FOR PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B

    Nov 1, 2010, 00:00

  • PSS29 INTERNATIONAL CO-VALIDATION OF A NEW INTERNATIONAL QUALITY OF LIFE INSTRUMENT SPECIFIC TO PHYSICAL APPEARANCE- BEAUTYQOL

    Nov 1, 2010, 00:00

  • BI2 MULTIPLE COHORT MODELING OF LONG-DURATION INTERVENTIONS- QUESTIONING TIME HORIZONS AND AGGREGATION ACROSS COHORTS

    Nov 1, 2010, 00:00

  • PIH20 EXPLORATORY COST-EFFECTIVENESS ANALYSIS OF THE ANTERIOR REPAIR OF THE PELVIC ORGAN PROLAPSE COMPARING ANTERIOR COLPORRHAPHY (CONVETIONAL SURGERY) VERSUS PROLIFT MESH, UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE

    Nov 1, 2010, 00:00

  • PDB94 MARKOV AND MONTE-CARLO MODELS IN THE PROGRESSION OF DIABETES MELLITUS- A LITTERATURE REVIEW TO IDENTIIFY THE FACTORS INFLUENCING THE CHOICE OF THE TYPE OF MODEL

    Nov 1, 2010, 00:00

  • PIH13 PATTERNS AND COSTS OF HOSPITALIZATIONS IN ELDERLY PATIENTS IN RIO DE JANEIRO, BRAZIL

    Nov 1, 2010, 00:00

  • PIN39 COST-EFFECTIVENESS OF NUCLEIC ACID TEST SCREENING IN BLOOD DONATION FOR HIV IN BRAZIL

    Nov 1, 2010, 00:00

  • PCN22 EFFICACY AND CARDIAC SAFETY OF TRASTUZUMAB (T) IN THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY-STAGE BREAST CANCER- A SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)

    Nov 1, 2010, 00:00

  • PSY52 DEVELOPMENT AND CONTENT VALIDATION OF A MULTICENTRIC CASTLEMANS DISEASE SYMPTOM SCALE

    Nov 1, 2010, 00:00

  • PIN58 REPORT ON A PILOT STUDY OF THE SIMPILL REALTIME MEDICATION ADHERENCE SYSTEM IN TUBERCULOSIS PATIENTS IN CAPE TOWN, SOUTH AFRICA

    Nov 1, 2010, 00:00

  • PIN26 EARLY VS. LATE DETECTION OF HIV IN UK- COST CONSEQUENCE STUDY

    Nov 1, 2010, 00:00

  • PIH28 WHY DO PATIENTS NOT ADHERE TO PRESCRIBED MEDICATION REGIMES? RESULTS OF TWO GERMAN SURVEYS

    Nov 1, 2010, 00:00

  • PCN88 COST-EFFECTIVENESS ANALYSIS OF CANCER TREATMENTS IN SOUTH OF IRAN

    Nov 1, 2010, 00:00

  • PDB79 DURATION OF FIRST INSULIN THERAPY IN PREVIOUSLY UNCONTROLLED TYPE 2 DIABETES- COMPARISON OF INSULINS GLARGINE, DETEMIR AND NPH AND ASSOCIATION WITH GLYCEMIC CONTROL

    Nov 1, 2010, 00:00

  • PDB51 COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE AND VERSUS BIPHASIC INSULIN ASPART FOR THE TREATMENT OF TYPE 2 DIABETES IN PORTUGAL- A LONG-TERM HEALTH ECONOMIC ANALYSIS

    Nov 1, 2010, 00:00

  • PMH22 RESULTS OF THE GERMAN IDA STUDY-ASSESSING THE FINANCIAL IMPACT OF INFORMAL CARE AMONGST COMMUNITY LIVING DEMENTIA PATIENTS

    Nov 1, 2010, 00:00

  • PSS31 VISION-RELATED QUALITY OF LIFE INSTRUMENTS (QOL) AFTER REFRACTIVE CATARACT SURGERY

    Nov 1, 2010, 00:00

  • PCN55 COST OF TREATMENT OF BREAST CANCER IN RUSSIA

    Nov 1, 2010, 00:00

  • PGI11 RISK FACTORS AND COSTS ASSOCIATED TO NSAIDS THERAPIES IN ITALY- AN ADMINISTRATIVE DATABASE ANALYSIS

    Nov 1, 2010, 00:00

  • PCV120 COMBINED MEDICATION CHOICE AND PATIENT PERSISTENCE IN HYPERTENSION THERAPY- EVIDENCE OF REAL-LIFE EFFECTIVENESS

    Nov 1, 2010, 00:00

  • PUK5 COMPARISON OF SF-6D, EQ-5D AND VAS IN HEMODIALYSIS THAI PATIENT

    Nov 1, 2010, 00:00

  • PDB27 INDIRECT COSTS OF ILLNESS FOR DIABETES IN PORTUGAL

    Nov 1, 2010, 00:00

  • PRS49 TESTING THE USABILITY AND LANGUAGE OF E-PRO TRANSLATIONS DURING LINGUISTIC VALIDATION- COGNITIVE DEBRIEFING ON E-DEVICE VS. PRINT OUTSCREENSHOTS

    Nov 1, 2010, 00:00

  • PMH22 HEALTH SCIENCE STUDENTS ATTITUDES TOWARD RESEARCH AND ITS IMPLICATIONS TO TEACHING

    Nov 1, 2010, 00:00

  • PCV124 IMPACT OF REGIONAL MEASURES IN THE SALES OF THE RENINANGIOTENSIN SYSTEM ANTAGONISTS IN SPAIN

    Nov 1, 2010, 00:00

  • PHP45 COSTS OF CARE UNDER A HEALTH CARE PLAN IN THE LAST 5 YEARS OF LIFE OF BENEFICIARIES-DATA FROM THE REAL WORLD

    Nov 1, 2010, 00:00

  • PRS13 ECONOMIC IMPACT OF NON-ADHERENCE TO GOLD GUIDELINES IN COPD PATIENTS IN PRIMARY CARE IN SPAIN

    Nov 1, 2010, 00:00

  • PMC40 ITEM CALIBRATION OF A GENERIC ROLE FUNCTIONING ITEM BANK

    Nov 1, 2010, 00:00

  • PCN26 PHARMACOECONOMIC EVALUATION OF NILOTINIB IN TREATING TAIWAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)

    Nov 1, 2010, 00:00

  • PCV92 THE HEALTH AND ECONOMIC IMPACT OF SWITCHING FROM ATORVASTATIN TO GENERIC SIMVASTATIN IN BELGIUM

    Nov 1, 2010, 00:00

  • PMH9 CHARACTERISTICS OF OUTPATIENTS INITIATED ON OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA IN JAPAN

    Nov 1, 2010, 00:00

  • PRS7 A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF CICLESONIDE WITH FLUTICASONE IN 1-1 AND 1-2 DOSE RATIOS IN THE TREATMENT OF BRONCHIAL ASTHMA

    Nov 1, 2010, 00:00

  • PCN12 EFFICACY OF SECOND LINE TREATMENTS IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER (MHRPC) IS NOT DEMONSTRATED BY PUBLISHED EVIDENCE FROM NONRANDOMIZED TRIALS

    Nov 1, 2010, 00:00

  • PSS33 REAL-LIFE DOSING OF BIOLOGICS IN PLAQUE PSORIASIS-A GERMAN SURVEY

    Nov 1, 2010, 00:00

  • PIN71 CLINICAL AND ECONOMIC BURDEN OF PEDIATRIC INFLUENZA IN NINE EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PSY56 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)- UNDERSTANDING THE BURDEN

    Nov 1, 2010, 00:00

  • PCV37 POTENTIAL FOR PATIENT CONFUSION FROM BRAND SUBSTITUTION OF STATINS IN AUSTRALIA

    Nov 1, 2010, 00:00

  • PCN93 COST-MINIMIZATION ANALYSIS OF XELOX (CAPECITABINE OXALIPLATIN) AS ADJUVANT TREATMENT IN STAGE III COLON CANCER UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE

    Nov 1, 2010, 00:00

  • PHP36 THE AVAILABILITY AND FUNDING OF ORPHAN DRUGS IN BOSNIA AND HERZEGOVINA IN COMPARISON WITH NEIGHBORING COUNTRIES

    Nov 1, 2010, 00:00

  • PCV49 THE EVALUATION OF CARE PATHWAYS AS A COMPLEX INTERVENTION- APPLICATION OF A METHODOLOGICAL FRAMEWORK

    Nov 1, 2010, 00:00

  • PIN13 BURDEN AND MEDICAL COSTS OF ANOGENITAL WARTS IN BANGKOK, THAILAND

    Nov 1, 2010, 00:00

  • PHP59 EVOLUTION OF PUBLIC EXPENDITURE WITH PHARMACEUTICAL CARE IN BRAZIL DURING THE PERIOD 2005-2008

    Nov 1, 2010, 00:00

  • PCN143 PRIMARY PREVENTION AS EXPANDED INDICATION TO MITIGATE COMPETITION-A CASE STUDY

    Nov 1, 2010, 00:00

  • CE2 COST-UTILITY ANALYSIS OF INTENSIVE LIFESTYLE INTERVENTIONS OR METFORMIN VERSUS STANDARD CARE IN THE PREVENTION OF TYPE 2 DIABETES IN HIGH-RISK SUBJECTS IN AN AUSTRALIAN SETTING. A SIMULATION ANALYSIS BASED ON THE LONG-TERM RESULTS OF TH ...

    Nov 1, 2010, 00:00

  • PRS45 OPTIMIZATION OF GUIDELINES SUSTAINABILITY BY EVALUATING FACTORS PREDICTING TREATMENT RESPONSE IN PATIENTS WITH ALLERGIC RHINITIS

    Nov 1, 2010, 00:00

  • PCN27 THE COST OF CHEMOTHERAPY SIDE EFFECTS

    Nov 1, 2010, 00:00

  • PCN87 PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT

    Nov 1, 2010, 00:00

  • PRS8 THE EFFECT OF UNCONTROLLED ASTHMA ON HEALTH-RELATED QUALITY OF LIFE AND RESOURCE USE IN JAPAN AND THE UNITED STATES

    Nov 1, 2010, 00:00

  • PIN44 COST-EFFECTIVENESS ANALYSIS OF 1 YEAR PEGINTERFERON ALFA-2A VERSUS 4 YEARS ENTECAVIR FOR THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B IN CHINA

    Nov 1, 2010, 00:00

  • PMC33 ESTIMATING HEALTH STATE UTILITY VALUES FOR COMORBID HEALTH CONDITIONS

    Nov 1, 2010, 00:00

  • PDB90 IMPROVING PATIENT CARE- RESULTS FROM THE TEXAS NEWBORN SCREENING PERFORMANCE MEASURES PROJECT

    Nov 1, 2010, 00:00

  • PCN119 COMPARISON OF EQ-5D SCORE BETWEEN TREATMENT WITH 4 CYCLES OF ANTHRACYCLINE FOLLOWED BY 4 CYCLES OF TAXANE AND 8 CYCLES OF TAXANE FOR NODE POSITIVE BREAST CANCER PATIENTS AFTER SURGERY- N-SAS BC 02 TRIAL

    Nov 1, 2010, 00:00

  • PIH61 CALIBRATION OF A DISCRETE EVENT SIMULATION MODEL OF NATURAL HISTORY OF HPV-RELATED DISEASES

    Nov 1, 2010, 00:00

  • PMH13 ASSOCIATION OF MEDICATION PERSISTENCE AND HEALTH-CARE UTILIZATION IN HIGH-COST PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH DULOXETINE OR VENLAFAXINE XR

    Nov 1, 2010, 00:00

  • PMH57 REVIEW OF CO-MORBIDITY OF EATING AND BODY DYSMORPHIC DISORDERS

    Nov 1, 2010, 00:00

  • PND32 INFLUENCE OF AGE ON REFILL-ADHERENCE RATES OF ANTIEPILEPTIC DRUGS IN SOUTH AFRICA

    Nov 1, 2010, 00:00

  • PUK2 COMORBIDITY EFFECT ON HOSPITAL READMISSION RATES IN PATIENTS WITH RENAL FAILURE

    Nov 1, 2010, 00:00

  • PHP12 THE PUBLICS PREFERENCE ON THE PRIORITIES IN HEALTH CARE

    Nov 1, 2010, 00:00

  • PSS38 USE OF CALL CENTRE METHODOLOGY TO COLLECT QUALITY OF LIFE (QOL) DATA IN A CLINICAL TRIAL- A CASE STUDY OF PATIENTS WITH DIABETIC MACULAR EDEMA (DME)

    Nov 1, 2010, 00:00

  • PDB29 STATUS AND TREATMENT OF TYPE 2 DIABETES IN CHINA

    Nov 1, 2010, 00:00

  • PHP14 THE JOINT COMMITTEE FOR NEW DRUGS EVALUATION IN SPAIN- 6 YEARS OF EXPERIENCE

    Nov 1, 2010, 00:00

  • PGI18 ECONOMICS OF A SYMPTOM BASED PATIENT MANAGEMENT APPROACH FOR GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), USING GERDQ, COMPARED TO AN INVASIVE APPROACH USING GASTROSCOPY AND PH-METRY

    Nov 1, 2010, 00:00

  • PHP113 LEVELS OF MEDICATION USE AMONG GERIATRIC PATIENTS IN ACUTE GERIATRIC CARE SETTINGS IN AUSTRIA

    Nov 1, 2010, 00:00

  • PCV21 THE RELATIVE EFFECTIVENESS PROFILE OF DRONEDARONE USING THE NUMBER NEEDED TO TREAT (NNT) APPROACH

    Nov 1, 2010, 00:00

  • PCV57 COST ANALYSIS OF THE MEDICINE TREATMENT OF SOUTH AFRICAN PATIENTS WITH METABOLIC SYNDROME

    Nov 1, 2010, 00:00

  • PRS15 THE POTENTIAL COST IMPACT OF USING A PEG HYDROGEL SEALANT TO PREVENT AIR LEAKS AFTER LUNG RESECTION SURGERY IN ITALY

    Nov 1, 2010, 00:00

  • PCV12 THE ECONOMIC BURDEN OF ATRIAL FIBRILLATION AND FLUTTER IN KOREA

    Nov 1, 2010, 00:00

  • PMH36 ECONOMIC EVALUATION ANALYSIS IN THE TREATMENT OF BIPOLAR DISORDER WITH ARIPIPRAZOLE AND OTHER ATYPICAL ANTIPSYCHOTIC DRUGS IN SPAIN

    Nov 1, 2010, 00:00

  • PCV81 THE COMPARATIVE ANALYSIS OF THE EFFECTIVENESS AND THE COSTS OF USING THE LOW-MOLECULAR-WEIGHT HEPARINS AND THE ORAL ANTICOAGULANTS FOR THE TREATMENT OF THE VENOUS THROMBOEMBOLISM IN POLAND

    Nov 1, 2010, 00:00

  • PHP39 A COMPARISON OF GENERIC AND ORIGINATOR BRAND DRUG PRICES BETWEEN JORDAN AND THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • AD4 THE IMPACT OF PHARMACIST INTERVENTION ON PATIENTS ADHERENCE TO ANTIDEPRESSANT MEDICATION AND PATIENTREPORTED OUTCOMES

    Nov 1, 2010, 00:00

  • PCN71 A COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES FROM PROSTATE CANCER IN 4 EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PIN48 PHARMACO-ECONOMICS OF ANTIBIOTICS

    Nov 1, 2010, 00:00

  • PSS1 META-ANALYSIS OF PARTIALLY HYDROLYZED 100-WHEY FORMULA VERSUS EXTENSIVELY HYDROLYZED FORMULAS IN THE PREVENTION OF ATOPIC DERMATITIS

    Nov 1, 2010, 00:00

  • PMH16 PHARMACIST-RUN METHADONE CLINIC IN A MALAYSIAN PUBLIC HEALTH CENTER- EVALUATING PATIENT SATISFACTION AND QUALITY OF LIFE OUTCOMES

    Nov 1, 2010, 00:00

  • PCV131 AN INTERNATIONAL COMPARISON OF DUAL ANTIPLATELET USE BY STENT TYPE AT 6 MONTHS FOLLOWING HOSPITAL DISCHARGE AFTER ACUTE CORONARY SYNDROME- RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR-II)

    Nov 1, 2010, 00:00

  • PDB30 GLYCEMIC CONTROL IS WORSE AND COMPLICATIONS MORE PREVALENT IN TYPE 2 DIABETES PATIENTS WITH A HIGHER BMI IN CHINA

    Nov 1, 2010, 00:00

  • PMC9 A NEO-RICARDIAN APPROACH TOWARD DISCOUNTING

    Nov 1, 2010, 00:00

  • PCV16 INPATIENT MANAGEMENT AND COSTS OF ACUTE CORONARY SYNDROMES IN FACULTY HOSPITAL- COMPARISON OF STEMI AND NON-STEMI

    Nov 1, 2010, 00:00

  • EQ2 TESTING THE PERFORMANCE OF THE NEWLY DEVELOPED VERSION OF THE EQ-5D WITH 5 LEVELS OF SEVERITY- APPLICATION ON A COHORT OF PATIENTS WITH CHRONIC HEPATIC DISEASES

    Nov 1, 2010, 00:00

  • PMS52 PREFERENCES OVER BENEFITS AND RISKS ASSOCIATED WITH THE USE OF NSAIDS- EVIDENCE FROM PATIENTS DIAGNOSED WITH OSTEOARTHRITIS (OA) IN UK

    Nov 1, 2010, 00:00

  • PHP17 ACCESSIBILITY TO ORPHAN DRUGS IN JAPAN-HAS THE ORPHAN DESIGNATION SYSTEM CONTRIBUTED?

    Nov 1, 2010, 00:00

  • PCN4 LIKELIHOOD OF A SUBSEQUENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) EVENT IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY (MEC/HEC)

    Nov 1, 2010, 00:00

  • PCV122 THE IMPACT OF A CLINICAL PHARMACIST INTERVENTION ON LIPID-LOWERING IN A PRIMARY CARE SETTING

    Nov 1, 2010, 00:00

  • PMS46 DOSING PROFILE COMPARISON BETWEEN PATIENTS WITH FIBROMYALGIA INITIATING DULOXETINE AND PREGABALIN IN 2007- A LARGE NATIONAL RETROSPECTIVE COHORT STUDY

    Nov 1, 2010, 00:00

  • PMS40 COST-EFFECTIVENESS OF DENOSUMAB COMPARED WITH GENERIC ALENDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN

    Nov 1, 2010, 00:00

  • PHP1 A STUDY EVALUATING PATTERN OF NON-PRESCRIPTION PURCHASE BY CONSUMERS FROM COMMUNITY PHARMACIES IN MALAYSIA

    Nov 1, 2010, 00:00

  • PCN85 SORAFENIB AND SUNITINIB IN METASTATIC RENAL CELL CARCINOMA- COST-EFFECTIVENESS ANALYSIS IN REIMBURSEMENT PROCEEDINGS VS. DATA FROM CLINICAL PRACTICE

    Nov 1, 2010, 00:00

  • PMS12 INCREASE OF INJECTION THERAPY ON PATIENTS WITH LOW BACK PAIN IN SOUTH KOREA (2006-2008)

    Nov 1, 2010, 00:00

  • PIN18 A PILOT COST-OF-ILLNESS STUDY ON LONG TERM COMPLICATIONS/ SEQUELAE FOLLOWING ACUTE OTITIS MEDIA (AOM) IN BELGIUM

    Nov 1, 2010, 00:00

  • PRS36 ADHERENCE TO MEDICATION AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH COPD- SGRQ-AN ALTERNATIVE METHOD TO IDENTIFY NONADHERENCE

    Nov 1, 2010, 00:00

  • PCN56 CLINICO-ECONOMIC ANALYSIS OF TREATMENT OF CHILDREN WITH RHABDOMYOSARCOMAS ON PROTOCOLS CWS

    Nov 1, 2010, 00:00

  • PIN1 COST AND QUALITY OF LIFE ISSUES ASSOCIATED WITH PROTEASE INHIBITOR-BASED COMBINATION THERAPY TO TREAT HEPATITIS C

    Nov 1, 2010, 00:00

  • PDB92 CLINICAL AND ECONOMIC CONSEQUENCES OF THE PHARMACOLOGICAL HYPOGLYCEMIC TREATMENT OF TYPE 2 DIABETES IN CROATIA

    Nov 1, 2010, 00:00

  • PMH54 USE OF THE ANALYTIC HIERARCHY PROCESS TO PRIORITIZE PATIENT-RELEVANT ENDPOINTS OF ANTIDEPRESSANT TREATMENT

    Nov 1, 2010, 00:00

  • PSY5 COST-EFFECTIVENESS OF DEFERASIROX VERSUS DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSAEMIA PATIENTS IN HONG KONG-AN INITIAL ANALYSIS

    Nov 1, 2010, 00:00

  • PMH43 HEALTH CARE UTILIZATION OF PATIENTS WITH DEPRESSION BEFORE AND AFTER INTIATING DULOXETINE

    Nov 1, 2010, 00:00

  • PIN15 THE ECONOMIC BURDEN OF SURGICAL SITE INFECTION USING THERAPEUTIC ANTIBIOTIC UTILIZATION MEASURE-COMPARISON OF TWO TIME PERIODS

    Nov 1, 2010, 00:00

  • PGI1 A SYSTEMATIC REVIEW OF THE DIAGNOSTIC ACCURACY OF SEROLOGIC TESTS IN THE DIAGNOSIS OF CELIAC DISEASE

    Nov 1, 2010, 00:00

  • PSY48 RESOURCE USE AND COSTS OF THE GASTRIC BYPASS SURGERY VERSUS CLINICAL TREATMENT FOR OBESE PATIENTS WITH COMORBIDITIES UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM

    Nov 1, 2010, 00:00

  • PHP35 THE IMPACT OF THE HOSPITAL FUNDING SYSTEM ON THE RANGE OF THE EXPENSIVE DRUGS AVAILABLE IN FRENCH AND ENGLISH HOSPITALS

    Nov 1, 2010, 00:00

  • PCN18 ECONOMIC IMPLICATIONS OF THE FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN THAILAND- A COST EFFECTIVENESS ANALYSIS

    Nov 1, 2010, 00:00

  • PCN163 EXTENDING FIXED EFFECT MODELS TO CENSORED COST DATA

    Nov 1, 2010, 00:00
  • «
  • 141 (current)
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • »